



Miguel Medina, EAB member

PhD, biochemist and molecular biologist
Deputy Scientific Director, CIBERNED, Madrid, Spain
Expertise: Cellular and molecular neuroscience,
Drug Discovery and Development, Alzheimer's and
dementia, Tauopathies, Biomarkers, Animal models
Contact person for **Ethical Rapporteurs of SP1 & SP4**

Miguel Medina, PhD

PhD in Biochemistry and Molecular Biology from the Universidad Autonoma of Madrid

He received postdoctoral training at the Center of Molecular Biology in Madrid (1993-1995), and then at the Center for Neurologic Diseases, Harvard Medical School in Boston (1996-2001), where he became Harvard Junior Faculty, and later moved to the Cavalieri Ottolenghi Scientific Institute in Turin as an independent Senior Scientist (2001-2003).

From 2003 until 2007 he headed the Drug Discovery Department in the Spanish biopharmaceutical company Noscira S.A., after which he was appointed Research Director in November 2007, leading a research team that moved two novel compounds from early discovery into phase II clinical trials for Alzheimer's and progressive supranuclear palsy. In March 2012 he was appointed Deputy Scientific Director of CIBERNED (Network Center for Biomedical Research in Neurodegenerative Diseases).

He is the Spanish representative at COEN (International Network of Centres of Excellence in Neurodegeneration) Oversight Group and serves as a chairman of the External Scientific Advisory Board of the CIEN Foundation.

He is also a member of the editorial advisory boards of various international journals. Dr. Medina has authored over 80 peer-reviewed scientific publications (h index=36, >4,800 citations) and is listed as co-inventor of 25 patents.